Structural Basis for the Rational Design of UAMC-1110-Based FAP Radiopharmaceuticals
Radioligands targeting fibroblast activation protein alpha (FAP) are promising tools for cancer diagnosis and therapy. However, the molecular binding mode of clinically established UAMC-1110-derived ligands such as FAPI-46 remains insufficiently characterized. To simplify synthesis while preserving key binding properties, we designed two novel derivatives - FAP-DD-101 (short aminoalkyl linker)…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
